This research aims to assess the long-term efficacy and safety of AXS-12 in narcolepsy type 1 patients post-SYMPHONY study.
Conducted as a Phase Three open-label extension and randomized-withdrawal trial.
Involved participants who completed the Phase 3 SYMPHONY study.
Demonstrated significant improvement in narcolepsy symptoms with AXS-12.
Reported an overall favorable safety profile for long-term use of AXS-12.
Abstract
The ENCORE study evaluated long-term efficacy and safety of AXS-12 (reboxetine) in participants with narcolepsy type 1 (NT1) who completed the Phase 3 SYMPHONY study.